Deutsches Ärzteblatt International presents new PRISCUS List

NewsGuard 100/100 Score

In the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2010; 107[31-32]: 543-51), Stephanie Holt, a clinical pharmacologist, and coauthors present the PRISCUS List: a list of medications that carry an increased risk of side effects when given to elderly patients.

The authors present the new list, which was developed specifically for Germany in the setting of a joint project entitled PRISCUS (Latin for "old and venerable"), and discuss its potential applications. Most patients take more medications as they grow older and thus run a greater risk of drug interactions and side effects. Medications that might cause side effects more frequently in elderly patients than they do in the overall population are called potentially inappropriate medications (PIM). A number of PIM lists already exist for countries other than Germany; these cannot be applied directly to the German situation because of differences between countries with respect to drug approval, prescribing practices, and treatment guidelines. The experts who created the PRISCUS list for Germany, proceeding on the basis of a literature search and a qualitative analysis of existing PIM lists from other countries, judged 83 medications to be potentially inappropriate for elderly patients. The authors of the article call the PRISCUS list an important aid in medical decision-making. The full list can be seen at www.priscus.net (in German).

Source:

Deutsches Ärzteblatt International

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.